A1C Reductions and Improved Patient-Reported Outcomes Following CGM Initiation in Insulin-Managed T2D
At the American Diabetes Association 80th Scientific Sessions, researchers from Dexcom presented the latest findings on a study of the Dexcom G6 Continuous Glucose Monitoring (CGM) System. The research looked at glycemic and quality of life indicators for a cohort of 39 commercially insured adults with T2D (age 25-65)* who were managed with intensive insulin therapy and used CGM for at least 12 weeks. Watch the five-minute poster presentation below.
Related Content
The clinical benefits of real time continuous glucose monitoring (rtCGM) use have been well demonstrated in both continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI)...
In this novel study, investigators examined not only the benefits of continuous glucose monitoring (CGM) augmented insulin therapy, they also looked at the impact of CGM separately in subjects on...